No abstract

No abstract

Excess dietary lipid uptake causes obesity, a major global health problem. Enterocyte-absorbed lipids are packaged into chylomicrons, which enter the bloodstream through intestinal lymphatic vessels called lacteals. Here, we show that preventing lacteal chylomicron uptake by inducible endothelial genetic deletion of () and (; also known as ) renders mice resistant to diet-induced obesity. Absence of NRP1 and FLT1 receptors increased VEGF-A bioavailability and signaling through VEGFR2, inducing lacteal junction zippering and chylomicron malabsorption. Restoring permeable lacteal junctions by VEGFR2 and vascular endothelial (VE)-cadherin signaling inhibition rescued chylomicron transport in the mutant mice. Zippering of lacteal junctions by disassembly of cytoskeletal VE-cadherin anchors prevented chylomicron uptake in wild-type mice. These data suggest that lacteal junctions may be targets for preventing dietary fat uptake.

FoxO transcription factors are important targets of insulin action. To better understand the role of FoxO proteins in the liver, we created transgenic mice expressing constitutively active FoxO1 in the liver using the ␣1-antitrypsin promoter. Fasting glucose levels are increased, and glucose tolerance is impaired in transgenic (TGN) versus wild type (WT) mice. Interestingly, fasting triglyceride and cholesterol levels are reduced despite hyperinsulinemia, and post-prandial changes in triglyceride levels are markedly suppressed in TGN versus WT mice. Activation of pro-lipogenic signaling pathways (atypical protein kinase C and protein kinase B) and the ability to suppress ␤-hydroxybutyrate levels are not impaired in TGN. In contrast, de novo lipogenesis measured with 3 H 2 O is suppressed by ϳ70% in the liver of TGN versus WT mice after refeeding. Gene-array studies reveal that the expression of genes involved in gluconeogenesis, glycerol transport, and amino acid catabolism is increased, whereas genes involved in glucose utilization by glycolysis, the pentose phosphate shunt, lipogenesis, and sterol synthesis pathways are suppressed in TGN versus WT. Studies with adenoviral vectors in isolated hepatocytes confirm that FoxO1 stimulates expression of gluconeogenic genes and suppresses expression of genes involved in glycolysis, the shunt pathway, and lipogenesis, including glucokinase and SREBP-1c. Together, these results indicate that FoxO proteins promote hepatic glucose production through multiple mechanisms and contribute to the regulation of other metabolic pathways important in the adaptation to fasting and feeding in the liver, including glycolysis, the pentose phosphate shunt, and lipogenic and sterol synthetic pathways.FoxO 2 transcription factors are important targets of insulin and growth factor action, and they contribute to the regulation of cell growth, differentiation, and metabolism (1-3). FoxO proteins form a subgroup within the family of Forkhead box (or Fox) transcription factors (4). Early studies indicated that Forkhead proteins interact with insulin response sequences (IRSs) in the promoter of the IGF-binding protein-1 (IGFBP-1) and the phosphoenolpyruvate carboxykinase (PEPCK) genes (5, 6) and that signaling through phosphatidylinositol 3Ј-kinase and protein kinase B (PKB) mediates IRS-dependent effects of insulin on gene expression (7). Genetic studies of Caenorhabditis elegans revealed that DAF-16, a FoxO transcription factor, is a major target of insulin-like signaling (8, 9). DAF-16 plays an important role in the adaptation to environmental stress, including nutrient restriction, and signaling through phosphatidylinositol 3Ј-kinase and PKB suppresses the function of DAF-16. Subsequent studies revealed that FoxO proteins contain highly conserved PKB phosphorylation sites (corresponding to Thr-24, Ser-256, and Ser-319 in human FoxO1) (10 -12) and that phosphorylation at these sites suppresses transactivation and promotes nuclear exclusion of FoxO proteins through multiple mechanisms (13)...